Jennifer Ling Lee Net Worth

The estimated Net Worth of Jennifer Ling Lee is at least 361 千$ dollars as of 9 March 2020. Jennifer Lee owns over 361 units of Moderna Inc stock worth over 351,355$ and over the last 8 years Jennifer sold MRNA stock worth over 9,866$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jennifer Lee MRNA stock SEC Form 4 insiders trading

Jennifer has made over 6 trades of the Moderna Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Jennifer sold 361 units of MRNA stock worth 9,866$ on 9 March 2020.

The largest trade Jennifer's ever made was exercising 4,019 units of Moderna Inc stock on 22 May 2017 worth over 319,551$. On average, Jennifer trades about 1,139 units every 85 days since 2016. As of 9 March 2020 Jennifer still owns at least 4,419 units of Moderna Inc stock.

You can see the complete history of Jennifer Lee stock trades at the bottom of the page.

What's Jennifer Lee's mailing address?

Jennifer's mailing address filed with the SEC is C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139.

Insiders trading at Moderna Inc

Over the last 6 years, insiders at Moderna Inc have traded over 2,713,086,305$ worth of Moderna Inc stock and bought 52,631 units worth 999,989$ . The most active insiders traders include Noubar Afeyan、David M. Rubenstein、Stephane Bancel. On average, Moderna Inc executives and independent directors trade stock every 2 days with the average trade being worth of 2,841,687$. The most recent stock trade was executed by Shannon Thyme Klinger on 6 September 2024, trading 1,139 units of MRNA stock currently worth 90,562$.

What does Moderna Inc do?

moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a

Complete history of Jennifer Lee stock trades at Standard BioTools Inc、Moderna Inc

Moderna Inc executives and stock owners

Moderna Inc executives and other stock owners filed with the SEC include:

• Stephane Bancel,
  Chief Executive Officer, Director
• Stephen Hoge,
  President
• Tal Zvi Zaks,
  Chief Medical Officer
• Juan Andres,
  Chief Technical Operations and Quality Officer
• Stephane Bancel,
  CEO & Director
• Stéphane Bancel,
  CEO & Director
• Dr. Stephen Hoge M.D.,
  Pres
• Dr. Stephen Hoge,
  Pres
• Juan Andres,
  Chief Technical Operations & Quality Officer
• David W. Meline,
  CFO & Principal Accounting Officer
• Francois Nader,
  Non-Executive Independent Director
• Noubar Afeyan,
  Non-Executive Independent Chairman of the Board, Co-Founder
• Israel Ruiz,
  Non-Executive Independent Director
• Robert Langer,
  Non-Executive Independent Director
• Stephen Berenson,
  Non-Executive Independent Director
• Paul Sagan,
  Non-Executive Independent Director
• Dr. Noubar B. Afeyan Ph.D.,
  Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board
• Elizabeth Tallett,
  Director
• Ray Jordan,
  Chief Corporate Affairs Officer
• Marcello Damiani,
  Chief Digital and Operational Excellence Officer
• Lori Henderson,
  General Counsel, Company Secretary
• Tracey Franklin,
  Chief Human Resource Officer
• David Meline,
  Chief Financial Officer
• Colleen Hussey,
  Sr. Mang. of Corp. Communications
• Shannon Thyme Klinger,
  Chief Legal Officer & Corp. Sec.
• Lori M. Henderson J.D., Esq.,
  Gen. Counsel & Corp. Sec.
• Lavina Talukdar CFA,
  Sr. VP & Head of Investor Relations
• Dr. Melissa J. Moore,
  Chief Scientific Officer & Member of Scientific Advisory Board
• Dr. John V. W. Reynders,
  Chief Information Officer
• Lorence H. Kim,
  Chief Financial Officer
• Elizabeth G Nabel,
  Director
• Noubar Flagship Ventures Fu...,
  
• Shannon Thyme Klinger,
  Chief Legal Officer
• Jennifer Ling Lee,
  Chief Accounting Officer
• Sandra Horning,
  Director
• Peter Barton Hutt,
  Director
• Moncef Slaoui,
  Director
• Ventures Fund Iv General Pa...,
  
• Edwin M Jr Kania,
  10% owner
• Ventures Fund Iv General Pa...,
  
• Goff Corinne Le,
  Chief Commercial Officer
• Paul Burton,
  Chief Medical Officer
• James M Mock,
  Chief Financial Officer
• Arpa Garay,
  Chief Commercial Officer
• David M. Rubenstein,
  Director